TtAgo-coupled-multiplex-digtal-RPA-CRISPR/Cas12a (TCMDC) for EGFR mutations detection

Area of Science:

• Biotechnology
• Molecular Diagnostics
• Oncology

Background:

• Epidermal Growth Factor Receptor (EGFR) is a critical target in non-small cell lung cancer (NSCLC) management.
• Existing EGFR detection methods face challenges with long detection times and false positives.
• Developing rapid, sensitive, and specific diagnostic tools is crucial for improving NSCLC patient outcomes.

Purpose of the Study:

• To develop a novel, rapid, and highly sensitive detection method for EGFR mutations in NSCLC.
• To address the limitations of current EGFR detection technologies in terms of speed and accuracy.
• To provide a potential clinical tool for early diagnosis and treatment monitoring of lung cancer.

Main Methods:

• Development of a Thermus thermophilus Argonaute (Ttago)-Coupled-Multiplex-digital-recombinase polymerase amplification (RPA)-Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas12a (TCMDC) assay.
• Integration of EGFR mutation template enrichment using TtAgo and double-guide DNA.
• Utilization of PAM-site-independent CRISPR RNAs targeting EGFR genes combined with RPA and CRISPR-Cas12a in a single pot.

Main Results:

• The TCMDC method achieved ultra-sensitive detection of EGFR mutations (down to 1 copy, 0.1%).
• The assay demonstrated visual detectability and high specificity.
• Successful validation using clinical serum samples from lung cancer patients, with detection completed within 1 hour.

Conclusions:

• The developed TCMDC method offers a rapid, sensitive, and visually detectable approach for EGFR mutation detection.
• This assay presents a promising and efficient clinical tool for lung cancer diagnosis and management.
• The method overcomes limitations of traditional techniques, potentially enhancing early detection and treatment strategies for NSCLC.